Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

p>1,252,4221,337,963   LONG-TERM DEBT

384,638363,696   DEFERRED TAX LIABILITIES, net

219,091159,328   OTHER LIABILITIES

279,049111,728Total liabilities

2,135,2001,972,715REDEEMABLE EQUITY

178,245207,307EQUITY:Cephalon Stockholders' Equity   Common stock, $0.01 par value

784780   Additional paid-in capital

2,407,5632,534,070   Treasury stock, at cost

(216,597)(208,427)   Accumulated earnings (deficit)

153,470(178,659)   Accumulated other comprehensive income

164,888114,194Total Cephalon stockholders' equity

2,510,1082,261,958Noncontrolling Interest

62,839216,115Total equity

2,572,9472,478,073$
4,886,392$
4,658,095CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Nine Months EndedSeptember 30,20102009CASH FLOWS FROM OPERATING ACTIVITIES:Net income

$
324,278$
210,919Adjustments to reconcile net income to net cash provided by operating activities:Deferred income tax expense (benefit)

(27,976)(40,182)Depreciation and amortization

163,049136,403Stock-based compensation expense

31,74036,710Amortization of debt discount and debt issuance costs

51,31841,273Loss (gain) on foreign exchange contracts

9,499(26,754)Gain on acquisition of Arana

-(10,008)IPR&D from Acusphere deconsolidation

-8,366Other

1,749(5,079)Changes in operating assets and liabilities:Receivables

(1,006)94,204Inventory

31,967(7,060)Other assets

7,48032,206Accounts payable, accrued expenses and deferred revenues

53,39589,192Other liabilities

5,047(43,059)Net cash provided by operating activities

650,540517,131CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment

(34,989)(43,647)Proceeds from sale of property and equipment

4,748-Cash balance from consolidation of variable interest entity<
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittcon is pleased to announce that the 2015 ... Scientific, have organized a session on nanotechnology for presentation ... Asia’s largest analytical and scientific instruments show, will be ... , The four speakers in this U.S. symposium, “Thinking ... Single Cells” will present their use of nanotechnology to ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3, Shire ... biopharmaceutical company, notes that Renovo Group plc, (LSE:,RNVO) ... latest Phase 2,studies of JUVISTA(R) (human recombinant TGFbeta3) ... (RN1001-319-1010)., Renovo’s press release can be found ...
... and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... company,focused on endocrine therapy and oncology, and Paladin ... company, announced today,that they have entered into a ... rights related to the manufacture, production, distribution,marketing, sale ...
... Feb. 29 Wyeth Pharmaceuticals,a division of Wyeth ... U.S. Food and,Drug Administration (FDA) has approved PRISTIQ(TM) ... treat adult patients with major depressive disorder (MDD). ... in the second,quarter of 2008., "We are ...
Cached Biology Technology:Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
(Date:8/28/2014)... mobile app called TX Invasives is now available from ... of Texas at Austin for identifying harmful non-native plant, ... species in the United States cause about $137 billion ... agricultural crops, clog waterways, kill native plants and more. ... app for reporting where invasive species occur, we,re more ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... Experimental Biology and Medicine has established the Distinguished Scientist ... have established them as leaders in biomedicine, and who ... of the Society have been named as the 2012 ... an awards ceremony on April 22nd in San Diego. ...
... (AZM) has been the most used insecticide in apple production ... a control for the codling moth, but a decision by ... end of this product,s use by tree fruit growers. ... to replace AZM. These new insecticides have unique modes of ...
... lizard moms tend to give their developing embryos short ... thing for the babies once they,re born, according to ... Biochemical Zoology. Stress changes the way animals ... are released that help the body to access stored ...
Cached Biology News:Lizard moms may prepare their babies for a stressful world 2
Pim-1 (12H8)...
Ets-1...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
Biology Products: